166 related articles for article (PubMed ID: 12559512)
1. Mitoxantrone in progressive multiple sclerosis: when and how to treat?
Gonsette RE
J Neurol Sci; 2003 Feb; 206(2):203-8. PubMed ID: 12559512
[TBL] [Abstract][Full Text] [Related]
2. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
3. Mitoxantrone therapy in rapidly worsening multiple sclerosis.
Benesova Y; Stourac P; Beranek M; Kadanka Z
Bratisl Lek Listy; 2005; 106(3):141-3. PubMed ID: 16026151
[TBL] [Abstract][Full Text] [Related]
4. Mitoxantrone for multiple sclerosis.
Martinelli Boneschi F; Vacchi L; Rovaris M; Capra R; Comi G
Cochrane Database Syst Rev; 2013 May; (5):CD002127. PubMed ID: 23728638
[TBL] [Abstract][Full Text] [Related]
5. [Mitoxantrone].
Pericot I; Montalban X
Neurologia; 2003; 18(6):318-23. PubMed ID: 12838451
[TBL] [Abstract][Full Text] [Related]
6. Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.
Rivera VM; Jeffery DR; Weinstock-Guttman B; Bock D; Dangond F
BMC Neurol; 2013 Jul; 13():80. PubMed ID: 23841877
[TBL] [Abstract][Full Text] [Related]
7. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
8. Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone.
Goffette S; van Pesch V; Vanoverschelde JL; Morandini E; Sindic CJ
J Neurol; 2005 Oct; 252(10):1217-22. PubMed ID: 15834643
[TBL] [Abstract][Full Text] [Related]
9. Mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis.
Hamzehloo A; Etemadifar M
Arch Iran Med; 2006 Apr; 9(2):111-4. PubMed ID: 16649351
[TBL] [Abstract][Full Text] [Related]
10. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
Foo EC; Russell M; Lily O; Ford HL
Mult Scler Relat Disord; 2020 Sep; 44():102330. PubMed ID: 32599468
[TBL] [Abstract][Full Text] [Related]
11. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.
Le Page E; Leray E; Taurin G; Coustans M; Chaperon J; Morrissey SP; Edan G
J Neurol Neurosurg Psychiatry; 2008 Jan; 79(1):52-6. PubMed ID: 17846110
[TBL] [Abstract][Full Text] [Related]
12. [Mitoxantrone as induction therapy in aggressive relapsing remitting multiple sclerosis: a descriptive analysis of 100 consecutive patients].
Le Page E; Leray E; Taurin G; Coustans M; Chaperon J; Edan G
Rev Neurol (Paris); 2006 Feb; 162(2):185-94. PubMed ID: 16518258
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis.
Gonsette RE
Expert Opin Pharmacother; 2004 Apr; 5(4):747-65. PubMed ID: 15102561
[TBL] [Abstract][Full Text] [Related]
14. Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosis.
Debouverie M; Vandenberghe N; Morrissey SP; Anxionnat R; Pittion-Vouyovitch S; Vespignani H; Edan G
Mult Scler; 2004 Aug; 10(4):407-12. PubMed ID: 15327038
[TBL] [Abstract][Full Text] [Related]
15. Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis.
Ramtahal J; Jacob A; Das K; Boggild M
J Neurol; 2006 Sep; 253(9):1160-4. PubMed ID: 16990994
[TBL] [Abstract][Full Text] [Related]
16. Clinical follow-up of 411 patients with relapsing and progressive multiple sclerosis 10 years after discontinuing mitoxantrone treatment: a real-life cohort study.
Chartier N; Epstein J; Soudant M; Dahan C; Michaud M; Pittion-Vouyovitch S; Guillemin F; Debouverie M; Mathey G
Eur J Neurol; 2018 Dec; 25(12):1439-1445. PubMed ID: 29996003
[TBL] [Abstract][Full Text] [Related]
17. Ten-year follow-up after mitoxantrone induction for early highly active relapsing-remitting multiple sclerosis: An observational study of 100 consecutive patients.
Lefort M; Le Corre G; Le Page E; Rizzato C; Le Port D; Michel L; Kerbrat A; Leray E; Edan G
Rev Neurol (Paris); 2022 Jun; 178(6):569-579. PubMed ID: 35181157
[TBL] [Abstract][Full Text] [Related]
18. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.
Zipoli V; Portaccio E; Hakiki B; Siracusa G; Sorbi S; Amato MP
J Neurol Sci; 2008 Mar; 266(1-2):25-30. PubMed ID: 17870094
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of mitoxantrone for the treatment of multiple sclerosis.
Jain KK
Expert Opin Investig Drugs; 2000 May; 9(5):1139-49. PubMed ID: 11060734
[TBL] [Abstract][Full Text] [Related]
20. [Aggressive multiple sclerosis. Definition and specific therapeutic indication].
Edan G
Presse Med; 2004 Feb; 33(3):187-91; discussion 192. PubMed ID: 15029034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
